Sriram Subramaniam is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia (UBC) and holds the Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design. His research leverages cryo-electron microscopy (cryo-EM) to advance structural biology and drug design, focusing on protein dynamics and therapeutic target identification. Education: PhD in Physical Chemistry (1987) from Stanford University; MSc in Chemistry (1981) from Indian Institute of Technology, Kanpur. Subramaniam's interdisciplinary work combines cryo-EM with computational tools and molecular biology to study protein structures at atomic resolution. His lab has pioneered cryo-EM applications in precision medicine, including mapping small molecule drugs on patient-specific cancer mutants. Recent publications (2024-2022) highlight his contributions to understanding SARS-CoV-2 immune evasion, structural mechanisms of ATPases, and AI integration in structural biology. His research spans viral entry mechanisms, CRISPR systems, and neurodegenerative disease pathways. Scientific Awards: Gobind Khorana Canada Excellence Research Chair NIH Director’s Award for Scientific Excellence Fellow of the Biophysical Society Breakthrough Prize nomination Based at the Djavad Mowafaghian Center for Brain Health, Subramaniam leads the Program in Cryo-EM Guided Drug Design, contributing to over 177 peer-reviewed publications with a career h-index of 58 and citations exceeding 12,340.
Jon Simon is the Joan Reinhart Professor and Professor of Applied Physics at Stanford University . He leads the Simon Lab , which explores the convergence of condensed matter physics , quantum optics , and quantum information science , focusing on creating synthetic materials from light and investigating topological and strongly correlated quantum systems. His research spans constructing photonic materials in quantum circuits, studying small quantum systems with strong correlations, and applying Hamiltonian engineering to realize exotic states of matter. The lab has achieved milestones like the first Mott insulator of photons and topologically insulating circuits . Collaborative projects with the Schuster Lab leverage superconducting quantum circuits for synthetic matter studies. Jon's students include Adam Shaw (PhD, now at Stony Brook) Lavanya Taneja (PhD, now at Atom Computing) Ruichao Ma (Postdoc, now faculty at Purdue) among others. The lab's recent publications focus on cavity arrays, hybrid quantum systems, and topological photonics. Research is supported by grants and affiliations with Stanford's Department of Applied Physics and interdisciplinary institutes.
Ning Zhang is an Assistant Professor in the Biology Department at James Madison University (JMU), joining in 2024. Her research focuses on enhancing crop resilience through molecular and biochemical studies of plant defense mechanisms against bacterial pathogens, alongside developing genome editing technologies for trait improvement. She holds a PhD in Horticulture and Crop Science from The Ohio State University (2016), an MS in Silviculture from Zhejiang Agriculture and Forestry University (2011), and a BS in Landscape Architecture from Shandong Agricultural University (2008). Research Interests: Dr. Zhang's lab investigates plant immunity pathways, CRISPR/Cas9 genome editing applications, and engineering crops for disease resistance. Her work integrates molecular biology, genetics, and biochemistry to tackle challenges posed by climate change and biotic/abiotic stresses. Recent Trends in Publications: Her articles concentrate on MAPK signaling pathways, NLR protein interactions, PP2C phosphatase regulation, and bacterial effector mechanisms in tomato and other crops. Key themes include immune system activation, pathogen recognition diversity, and transgenic plant development. Lab Information: The Zhang Lab at JMU is part of the Department of Biology, focusing on plant biotechnology solutions for agricultural sustainability. They collaborate on projects involving CRISPR-based gene editing and stress tolerance research.
Supratik Guha is a Professor at the Pritzker School of Molecular Engineering and Senior Advisor to Argonne National Laboratory's Physical Sciences and Engineering directorate. His work bridges industrial R&D with academic and national lab research, focusing on quantum computing , semiconductor materials , and sensor networks for water and soil monitoring. Guha leads Argonne’s quantum information science strategy and serves as Faculty Director for the University of Chicago Center in Delhi. Education: PhD in Materials Science (USC, 1991), BTech in Engineering Physics (IIT Kharagpur, 1985) Research interests span multiple domains: Quantum technologies focusing on erbium-doped oxides for quantum memory and quantum interconnects Sensor networks for soil and water quality monitoring using cyberphysical systems Nanofabrication techniques including controlled spalling for heterogeneous material integration Advanced memory technologies exploring ferroelectric and optically addressable memory at atomic scales Scientific awards include: Election to National Academy of Engineering (2015) APS Prize for Industrial Applications of Physics (2015) Vannevar Bush Faculty Fellow (2018) Fellow of Materials Research Society and American Physical Society IBM Corporate Award (2013) Advising notable students like Manish Kumar Singh (co-founder memQ ), Cheng Ji (now at Intel), and Vamsi Nittala (now at Micron Technology). His group contributes to major DOE , NSF , and USDA funded projects including: Q-NEXT - DOE National Quantum Information Center AIFARMS - NSF/USDA AI for Agriculture Institute Thoreau Project - Geospatial sensor networks Labs and teams operate across University of Chicago and Argonne National Lab , with facilities for molecular beam epitaxy , nanofabrication , and optical/electrical characterization . The group has spawned startups like memQ (quantum networking) and K1 Semiconductors (wide-bandgap material transfer).
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Rebecca Schulman is an Associate Professor in the Department of Chemical and Biomolecular Engineering at the Whiting School of Engineering, Johns Hopkins University. She holds secondary appointments in Chemistry and Computer Science and is affiliated with multiple interdisciplinary institutes, including the Institute for NanoBioTechnology, the Hopkins Extreme Materials Institute, the Chemistry-Biology Interface Program, the Center for Cell Dynamics, and the Laboratory for Computational Sensing and Robotics. She currently co-directs the Passport to Future Technology Leadership program for PhD students. Research Interests: Schulman's research lies at the intersection of DNA nanotechnology, synthetic biology, and smart materials. Her group develops intelligent, adaptive biomolecular materials and nanostructures by integrating concepts from materials science, biochemistry, circuit design, and soft matter physics. The team focuses on engineering dynamic self-assembly processes using DNA to create reconfigurable materials, molecular circuits, and autonomous soft micro-robots. Key themes include self-healing nanostructures, feedback-regulated crystallization, programmable hydrogels, and synthetic genetic networks for materials control. Publication Trends: Her recent publications demonstrate a consistent focus on using DNA-based chemical reaction networks to program spatial and temporal behavior in materials. The work spans from fundamental mechanisms like catalytic polymerization and crystal growth regulation to applications in soft robotics, self-wiring circuits, and synthetic pattern formation. The research is highly interdisciplinary, combining synthetic biology with materials engineering to achieve life-like functionalities in non-living systems. Scientific Awards: AIMBE Fellowship Award Vannevar Bush Faculty Fellowship Award Hartwell Individual Biomolecular Research Award President’s Early Career Award in Science and Engineering (PECASE) DARPA Young Faculty Award DARPA Directors Fellowship NSF CAREER Award Turing Scholar Award DOE Early Career Award Advising and Grants: Schulman mentors graduate students and leads a vibrant research group focused on next-generation biomolecular engineering. Her work is supported by major federal grants, including the NSF CAREER, DOE Early Career, DARPA, and the Vannevar Bush Fellowship—a prestigious Department of Defense award for basic research. She is actively involved in training future leaders through programs like the Passport to Future Technology Leadership. Labs and Teams: The Schulman Lab at Johns Hopkins is a multidisciplinary team working on DNA-powered materials and molecular programming. The lab is embedded within several collaborative centers, enabling strong cross-departmental and cross-institutional research. Their work combines experimental biochemistry with theoretical modeling to design and implement complex molecular systems.
Di Zhu is a Presidential Young Professor in the Department of Materials Science and Engineering at the National University of Singapore (NUS). He holds a B.Eng. from Nanyang Technological University and M.Sc./Ph.D. from MIT, both in Electrical Engineering. His postdoctoral research at Harvard focused on lithium niobate integrated photonics and superconducting detectors. He previously worked as a research scientist and PI at A*STAR's Institute of Materials Research and Engineering (IMRE). Research Interests : Integrated quantum photonics, superconducting detectors, nonlinear optics, and nanofabrication. His group develops scalable quantum photonic devices using lithium niobate and superconducting materials, emphasizing applications in quantum computing, communication, and sensing. Awards : National Research Foundation (NRF) Fellowship Harvard Quantum Initiative (HQI) Postdoctoral Fellowship MIT Jin-Au Kong Thesis Award Advising & Recruitment : Actively recruiting postdocs, PhD students, and interns in areas like integrated photonics, quantum optics, and superconducting detectors. Positions include work on thin-film lithium niobate, quantum simulation, and microwave-optical transduction. Group website: dizhulab.org .
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Réka Albert is a Distinguished Professor of Physics at Pennsylvania State University, affiliated with the Eberly College of Science. Her research focuses on the application of network science to biological systems, including signal transduction networks, ecological interactions, and cancer systems biology. She holds editorial roles at npj Systems Biology and Applications , IET Systems Biology , and Bulletin of Mathematical Biology . Education: Ph.D. in Physics from the University of Notre Dame (2001), M.S. and B.S. from Babeș-Bolyai University, Romania (1995-1996). Research Interests: Modeling complex systems using network theory; Boolean network analysis of biological pathways; ecological community dynamics; systems-level understanding of disease mechanisms (e.g., cancer, AML). Her work bridges theoretical physics, computational biology, and experimental data to predict system behavior and therapeutic strategies. Awards: External member of the Hungarian Academy of Sciences (2016), APS Maria Goeppert-Mayer Award (2011), NSF CAREER Award (2007), and Alfred P. Sloan Fellowship (2004). Grants/Support: NSF awards (MCB 1715826, IIS 1814405), ARO MURI on hyperuniform systems, and collaborations with biologists like Sarah Assmann (plant signaling) and Katriona Shea (ecology). Labs/Teams: Leads a multidisciplinary research group at Penn State, mentoring over 20 PhD alumni and current students like Eli Newby and Fatemeh Nasrollahi. Active in developing tools like pystablemotifs for Boolean network analysis.
Patricia Champion is a Professor in the Department of Biological Sciences at the University of Notre Dame, where she holds the title of Notre Dame Collegiate Professor. Her research is centered on the molecular mechanisms of mycobacterial pathogenesis, with a focus on protein transport and virulence. She is affiliated with the Eck Institute for Global Health and the Center for Rare and Neglected Diseases. PhD in Molecular Biology, Princeton University (2003) B.S. in Biological Sciences, Carnegie Mellon University (1998) Her research interests lie in understanding how pathogenic mycobacteria, including Mycobacterium tuberculosis and M. marinum , cause disease through targeted protein secretion, particularly via the Type VII (ESX-1) secretion system. She investigates how secreted proteins function as effectors and regulate gene expression, and how post-translational modifications like acetylation influence virulence. Her lab employs an interdisciplinary approach combining genetics, molecular biology, proteomics, and transcriptomics. The recent publications highlight a strong focus on ESX-1-mediated secretion, identification of novel substrates, regulatory mechanisms (e.g., WhiB6, EspM), and post-translational modifications. The work spans fundamental bacterial physiology to host-pathogen interactions, contributing to the broader goal of identifying targets for anti-virulence therapeutics against tuberculosis. Her scientific recognition includes being named a Notre Dame Collegiate Professor, a distinguished honor reflecting her scholarly excellence. Dr. Champion leads an active research laboratory committed to fostering an inclusive and respectful environment, emphasizing core values such as integrity, teamwork, and excellence. Her lab's work is supported by ongoing research grants, though specific funding sources are not detailed in the text. The Champion Lab operates within the Department of Biological Sciences and collaborates with key institutes at Notre Dame focused on global and neglected diseases.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Professor David Grainger is a faculty member at the University of Birmingham's School of Biosciences, specializing in Molecular Microbiology. He leads the Grainger Lab, focusing on bacterial chromosome biology, pathogenicity, and antibiotic resistance. His research integrates high-throughput techniques and single-molecule analysis to study gene regulation and bacterial pathogenesis. Education: PhD (2004), PGCE (2000), BSc (1999) in Biochemistry from the University of Birmingham. Affiliations: Part of the Institute of Microbiology and Infection (IMI), collaborating with experts in genomics, proteomics, and structural biology. Research Interests: Deciphering chromosome biology of pathogenic bacteria, including transcriptional regulation, toxin production control, and antibiotic resistance pathways. Utilizes cutting-edge methods like Hi-C for 3D chromatin analysis and single-molecule microscopy. Recent Articles: Focused on transposon capture mechanisms, bacterial promoter diversity, and quorum sensing signaling. Highlights include studies on Salmonella regulons and Vibrio cholerae biofilm suppression. Awards: Wellcome Trust Career Development Fellowship (2008), Runner-up in 'Science Snaps' competition for scientific communication. Grants: Career Development Fellowship-funded establishment of his research group at the University of Warwick (2008). Labs/Teams: Grainger Lab at the University of Birmingham, part of the IMI network. Engages in public science outreach via Twitter and lab website.
Benjamin Machta is an Assistant Professor of Physics at Yale University, affiliated with the Department of Physics and the QBio Institute. He holds a BS from Brown University and a PhD from Cornell University, followed by a postdoctoral fellowship at Princeton University. His research focuses on applying theoretical physics to understand biological systems, particularly leveraging statistical physics and information theory to study biological membranes near critical points and the energetic constraints of biological signaling. Education: BS in Physics (Brown University), PhD in Physics (Cornell University), Postdoc at Princeton University (Lewis-Sigler Theory Fellow). Research Interests include: membrane criticality, phase transitions in biological systems, information-theoretic limits in organism function, and energy dissipation in biological processes. His work often bridges theoretical models with experimental data, such as collaborations with Sarah Veatch’s lab on membrane phase behavior. Publications highlight themes like membrane criticality, protein phase separation, and energy constraints in signaling. His group’s current projects explore cochlear mechanics, thermodynamic control in biological systems, and the role of criticality in sensory systems. Awards: 2019 Simons Investigator Award. Lab Affiliations: QBio Institute and Department of Physics at Yale, located in YSB-C164. Group members include postdocs Isabella Graf and Michael Abbott, and graduate students Asheesh Momi, Mason Rouches, and others.
Dan A. Dixon is a Professor and Associate Director of Community Outreach and Engagement at the Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences (UAMS), where his research focuses on post-transcriptional gene regulation mechanisms in cancer pathogenesis. His academic credentials include: Ph.D. from Northwestern University B.A. from Augustana University Dr. Dixon's research centers on RNA-binding proteins (notably HuR and tristetraprolin) and their role in destabilizing oncogenic mRNA networks. His laboratory investigates how dysregulation of these post-transcriptional controllers permits overexpression of tumor-promoting genes involved in proliferation, angiogenesis, and metastasis. Key focus areas include colorectal cancer mechanisms, autophagy regulation via Rab27B, stress granule dynamics in mutant p53 contexts, and extracellular vesicle-mediated tumor microenvironment activation. Analysis of his 2022-2025 publications reveals intensifying work on XPO1 inhibition for colorectal cancer chemoprevention, Rab27B-autophagy axis characterization, and mutant p53 vulnerabilities. His studies consistently employ molecular techniques, mouse models (APC Min/+ ), and translational approaches to identify biomarkers and therapeutic targets. Dr. Dixon maintains active laboratory facilities at WPRCI 947 and 951, directing research that bridges fundamental RNA biology with clinical oncology applications. His leadership in community outreach complements his bench-to-bedside research philosophy.
Professor Urs Jenal is a Full Professor at the Biozentrum of the University of Basel, Switzerland, where he has led research on bacterial signal transduction since 2008. His laboratory investigates the molecular mechanisms of bacterial persistence and antibiotic resistance, with particular focus on pathogens causing chronic infections in humans. Previously, he served as Associate Professor (2002-2008) and Assistant Professor (1996-2002) at the same institution, and completed postdoctoral training at Stanford University and ETH Zurich. Education 2000: Habilitation and VENIA DOCENDI in Microbiology, University of Basel 1987-1991: PhD in Molecular Microbiology, ETH Zurich (supervisor: Prof. T. Leisinger) 1982-1986: Studies of Experimental Biology, ETH Zurich 1977-1981: Gymnasium with Matura Type C, Chur Research Focus Prof. Jenal's research centers on understanding how bacterial pathogens persist in the human body despite antibiotic treatments. His laboratory investigates cyclic nucleotides, particularly c-di-GMP, as signaling molecules that control bacterial biofilm formation, virulence, and antibiotic tolerance. His team studies pathogenic Escherichia coli causing recurrent urinary tract infections and Pseudomonas aeruginosa causing long-term lung infections in cystic fibrosis patients. Recent work has revealed how "sleeping" bacteria survive antibiotic treatments and how pathogens breach respiratory epithelia through goblet cell invasion. Scientific Recognition 2014: Elected member of the European Academy of Microbiology (EAM) 2013: ERC Advanced Investigator Award 2012: Elected member of the European Molecular Biology Organization (EMBO) 2011: Elected member of the American Academy of Microbiology (AAM) Mentorship and Collaborations Prof. Jenal has mentored numerous PhD students and postdocs, many receiving awards for their research. His laboratory is part of the NCCR AntiResist initiative focused on developing novel approaches against antibiotic resistance. He collaborates extensively with clinical researchers and has developed innovative models, including human mini-lungs, to investigate pathogen-host interactions. His recent publications demonstrate how understanding bacterial persistence mechanisms can lead to new therapeutic strategies against chronic infections.
